Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Xometry, Inc. (NASDAQ:XMTR – Get Rating) has been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $51.88.
Several equities research analysts recently issued reports on XMTR shares. UBS Group reduced their target price on shares of Xometry from $55.00 to $45.00 and set a “neutral” rating for the company in a report on Friday, November 11th. Citigroup reissued a “buy” rating and issued a $55.00 target price on shares of Xometry in a report on Tuesday, December 13th. Royal Bank of Canada reduced their target price on shares of Xometry from $60.00 to $54.00 and set an “outperform” rating for the company in a report on Friday, November 11th. Lake Street Capital started coverage on shares of Xometry in a report on Wednesday, December 14th. They issued a “sell” rating and a $28.00 target price for the company. Finally, The Goldman Sachs Group reduced their target price on shares of Xometry from $64.00 to $57.00 and set a “buy” rating for the company in a report on Monday, November 14th.
Xometry Price Performance
Shares of NASDAQ:XMTR opened at $27.65 on Friday. The firm’s 50 day moving average price is $41.05 and its 200-day moving average price is $45.34. Xometry has a twelve month low of $26.61 and a twelve month high of $64.35. The company has a quick ratio of 6.21, a current ratio of 6.30 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $1.23 billion, a PE ratio of -16.96 and a beta of -0.20.
Xometry (NASDAQ:XMTR – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.02. Xometry had a negative net margin of 21.58% and a negative return on equity of 15.52%. The firm had revenue of $103.57 million for the quarter, compared to analysts’ expectations of $102.73 million. Equities research analysts expect that Xometry will post -1.47 EPS for the current year.
Insider Buying and Selling at Xometry
In related news, CTO Matthew Leibel sold 1,442 shares of the firm’s stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $30.61, for a total value of $44,139.62. Following the completion of the transaction, the chief technology officer now directly owns 33,733 shares of the company’s stock, valued at $1,032,567.13. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO James M. Rallo sold 2,711 shares of the firm’s stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $30.64, for a total value of $83,065.04. Following the completion of the transaction, the chief financial officer now directly owns 18,976 shares of the company’s stock, valued at $581,424.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CTO Matthew Leibel sold 1,442 shares of the firm’s stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $30.61, for a total transaction of $44,139.62. Following the completion of the transaction, the chief technology officer now directly owns 33,733 shares of the company’s stock, valued at $1,032,567.13. The disclosure for this sale can be found here. Insiders sold a total of 139,237 shares of company stock valued at $6,613,518 in the last three months. 30.21% of the stock is currently owned by corporate insiders.
Institutional Trading of Xometry
A number of institutional investors have recently bought and sold shares of the stock. Advisors Asset Management Inc. lifted its position in Xometry by 22.5% in the third quarter. Advisors Asset Management Inc. now owns 1,685 shares of the company’s stock worth $96,000 after buying an additional 309 shares during the last quarter. MCF Advisors LLC bought a new stake in Xometry in the third quarter worth $34,000. Quantbot Technologies LP bought a new stake in Xometry in the third quarter worth $35,000. UBS Group AG lifted its position in Xometry by 81.1% in the third quarter. UBS Group AG now owns 1,869 shares of the company’s stock worth $106,000 after buying an additional 837 shares during the last quarter. Finally, LVW Advisors LLC lifted its position in Xometry by 11.4% in the second quarter. LVW Advisors LLC now owns 9,326 shares of the company’s stock worth $316,000 after buying an additional 951 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.
Xometry Company Profile
(Get Rating)
Xometry, Inc operates a marketplace that enables buyers to source manufactured parts and assemblies in the United States and internationally. It provides CNC machining, milling, and turning services; sheet, laser, waterjet, and plasma cutting services; and sheet metal forming services. The company also offers 3D printing services, such as carbon digital light synthesis, fused deposition modeling, HP multi jet fusion, PolyJet, selective laser sintering, stereolithography, metal 3D printing service, direct metal laser sintering, and metal binder jetting; and injection molding services, including plastic injection, over, insert, and prototype molding, as well as bridge and production tooling.
Read More
- Get a free copy of the StockNews.com research report on Xometry (XMTR)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xometry, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Xometry wasn’t on the list.
While Xometry currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company’s CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
